Trial Profile
A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Benmelstobart (Primary) ; Catequentinib (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 09 Sep 2020 Status changed from not yet recruiting to recruiting.
- 26 Aug 2020 New trial record